GARDEN GROVE, California, Sept. 18, 2012 /PRNewswire/ -- HYCOR Biomedical, Inc., a leading manufacturer and marketer of in vitro diagnostic products for the global allergy, autoimmune and urinalysis markets, today announced the opening of its European center of operations located in Kassel, Germany. The facility primarily houses field and technical service as well as customer service functions.

"As we continue to branch out internationally, we are thrilled to reestablish our physical presence in Europe with this new facility in Kassel, Germany," said Dick Aderman, CEO, HYCOR. "The opening of this facility is part of our global growth strategy and marks an important step in strengthening our support and commitment to EMEA (Europe, the Middle East and Africa) customers. The facility will be instrumental in handling current and future distributor and customer needs."

The new center of operations, which opened in early August, supports HYCOR's expansion in EMEA and demonstrates HYCOR's commitment and dedication to this important market.

Contact information
HYCOR Europe / Biocrest B.V.
Waldauer Weg 84
34253 Kassel - Lohfelden
Germany
Phone: +49-561-816-7000 - 0
Fax: +49-561-816-7000 - 99
Customer Service: cseurope@hycorbiomedical.com
Technical & Application Service: techserviceseurope@hycorbiomedical.com   

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.hycorbiomedical.com.

About Linden LLC
Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden's portfolio includes BarrierSafe Solutions International, Behavioral Centers of America, Corpak MedSystems, Drayer Physical Therapy Institute, HYCOR Biomedical, and Ranir. For additional information, please visit www.lindenllc.com.